Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Subcutaneous C1-INH in HAE (COMPACT OLE)
NCT02316353Phase 3Completed
- Sponsor
- CSL Limited
- Start
- Dec 2014
- Primary completion
- Sep 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
A Phase 3 trial of c1-esterase inhibitor in hereditary angioedema (HAE), sponsored by CSL Limited. Started Dec 2014; status: completed.
02
Drugs
c1-esterase inhibitor
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT02316353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02316353.